Factor Xa inhibitor rivaroxaban suppresses experimental abdominal aortic aneurysm progression via attenuating aortic inflammation
Y Ding, X Li, M Zhou, L Cai, H Tang, T Xie, Z Shi… - Vascular …, 2021 - Elsevier
Objective Rivaroxaban is a specific factor Xa (FXa) inhibitor for venous thromboembolism
treatment. Recently, increasing evidence have reported the beneficial effects of rivaroxaban
on treating cardiovascular disorders such as coronary and peripheral artery disease.
However, its potential influence on abdominal aortic aneurysm (AAA) remains unclear. This
study aims to investigate whether rivaroxaban treatment could attenuate experimental AAA
progression and its related mechanisms. Approaches and results In human aneurysmal …
treatment. Recently, increasing evidence have reported the beneficial effects of rivaroxaban
on treating cardiovascular disorders such as coronary and peripheral artery disease.
However, its potential influence on abdominal aortic aneurysm (AAA) remains unclear. This
study aims to investigate whether rivaroxaban treatment could attenuate experimental AAA
progression and its related mechanisms. Approaches and results In human aneurysmal …
